TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Procalcitonin-Guided Antimicrobial Discontinuation Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Sepsis
Brief Summary: The current study aims to validate the diagnostic use of PCT assessing its capability to individualize and shorten the duration of antibiotic therapy in critically ill patients with suspected or confirmed sepsis.

In particular, no well-designed intervention study has properly examined the following hypothesis: A PCT-guided antibiotic discontinuation strategy enables to reduce antibiotic treatment duration in critically ill patients with suspected or documented sepsis, without harming patient safety.


Options:
A: Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Release of test results; Type: EXPERIMENTAL; Interventions: Other: Release of test results | Intervention Type: OTHER; Name: Release of test results; Assigned to Arm(s): Release of test results
B: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy
C: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
D: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Procalcitonin-Guided Antimicrobial Discontinuation Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Sepsis
Brief Summary: The current study aims to validate the diagnostic use of PCT assessing its capability to individualize and shorten the duration of antibiotic therapy in critically ill patients with suspected or confirmed sepsis.

In particular, no well-designed intervention study has properly examined the following hypothesis: A PCT-guided antibiotic discontinuation strategy enables to reduce antibiotic treatment duration in critically ill patients with suspected or documented sepsis, without harming patient safety.


Options:
A: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
C: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
D: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Procalcitonin-Guided Antimicrobial Discontinuation Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Sepsis
Brief Summary: The current study aims to validate the diagnostic use of PCT assessing its capability to individualize and shorten the duration of antibiotic therapy in critically ill patients with suspected or confirmed sepsis.

In particular, no well-designed intervention study has properly examined the following hypothesis: A PCT-guided antibiotic discontinuation strategy enables to reduce antibiotic treatment duration in critically ill patients with suspected or documented sepsis, without harming patient safety.


Options:
A: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
C: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
D: Arm Label: Procalcitonin-guided group; Type: N/A; Interventions: Other: Literature search | Arm Label: Routine practice group; Type: N/A; Interventions: Other: Literature search | Intervention Type: OTHER; Name: Literature search; Assigned to Arm(s): Procalcitonin-guided group, Routine practice group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Procalcitonin-Guided Antimicrobial Discontinuation Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Sepsis
Brief Summary: The current study aims to validate the diagnostic use of PCT assessing its capability to individualize and shorten the duration of antibiotic therapy in critically ill patients with suspected or confirmed sepsis.

In particular, no well-designed intervention study has properly examined the following hypothesis: A PCT-guided antibiotic discontinuation strategy enables to reduce antibiotic treatment duration in critically ill patients with suspected or documented sepsis, without harming patient safety.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Amikacin (BAY41-6551) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Amikacin (BAY41-6551) | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Amikacin (BAY41-6551); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Amikacin (BAY41-6551); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
B: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
C: Arm Label: 8 days of antibiotic treatment; Type: EXPERIMENTAL; Interventions: Drug: Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin, Drug: compare 8 to15 days of antibiotic treatment | Arm Label: 15 days antibiotic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: compare 8 to15 days of antibiotic treatment | Intervention Type: DRUG; Name: Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; Assigned to Arm(s): 8 days of antibiotic treatment | Intervention Type: DRUG; Name: compare 8 to15 days of antibiotic treatment; Assigned to Arm(s): 15 days antibiotic treatment, 8 days of antibiotic treatment
D: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wait and See Antibiotic Prescription for Acute Otitis Media: A Randomized Controlled Trial
Brief Summary: To determine if a wait and see prescription for ear infections in childhood reduces use of antibiotics compared to an immediate prescription


Options:
A: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amoxicillin-clavulanate, Drug: Placebo | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BEHAVIORAL; Name: Prescription Fill Status; Assigned to Arm(s): N/A
C: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wait and See Antibiotic Prescription for Acute Otitis Media: A Randomized Controlled Trial
Brief Summary: To determine if a wait and see prescription for ear infections in childhood reduces use of antibiotics compared to an immediate prescription


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: BEHAVIORAL; Name: Prescription Fill Status; Assigned to Arm(s): N/A
D: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amoxicillin-clavulanate, Drug: Placebo | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients
Brief Summary: The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.


Options:
A: Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
C: Arm Label: Low-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: High-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolic Acid (MPA), Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Mycophenolic Acid (MPA); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Cyclosporine A (CsA); Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group
D: Arm Label: Everolimus + Low dose CsA +PD; Type: EXPERIMENTAL; Interventions: Drug: Everolimus + Low dose CsA +PD | Arm Label: Myfortic+ Standard CsA + PD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Myfortic+ Standard CsA + PD | Intervention Type: DRUG; Name: Everolimus + Low dose CsA +PD; Assigned to Arm(s): Everolimus + Low dose CsA +PD | Intervention Type: DRUG; Name: Myfortic+ Standard CsA + PD; Assigned to Arm(s): Myfortic+ Standard CsA + PD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.
Brief Summary: Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Multi-nutrient supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multi-nutrient supplement | Arm Label: Placebo + Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation, Other: Placebo | Arm Label: Multi-nutrient + Behavioral Activation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multi-nutrient supplement, Behavioral: Behavioral Activation | Intervention Type: DIETARY_SUPPLEMENT; Name: Multi-nutrient supplement; Assigned to Arm(s): Multi-nutrient + Behavioral Activation, Multi-nutrient supplement | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Multi-nutrient + Behavioral Activation, Placebo + Behavioral Activation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Placebo + Behavioral Activation
D: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.
Brief Summary: Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
B: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group
C: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.
Brief Summary: Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
B: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo

Answer: A